Following the advent of GLP-1 drugs, from Ozempic® to Mounjaro®, I continue to see more and more patients who have lost significant weight, with loss of facial volume, skin laxity, and a more tired and aged appearance.

In many cases, the problem is not just the weight loss itself, but the inability to recognize the right moment to stop, continuing to lose weight beyond a healthy and harmonious limit.

It is in this context that the expression “Ozempic face” has spread, used to describe the changes that can appear on the face after significant weight loss: hollowing of the cheeks and temples, greater prominence of furrows, and a reduction in skin tone and firmness. This is not a specific effect of the drug, but primarily the consequence of the rapid loss of subcutaneous adipose tissue that supports and structures the face.

Aesthetic medicine can play an important role not in countering weight loss, but in managing its consequences on the tissues. The goal is to recover, when necessary, part of the lost volumes and improve skin quality, elasticity, and firmness, avoiding excessive or artificial results. Collagen biostimulators, targeted treatments, and, in some cases, a careful assessment of volumes can be integrated into a personalized strategy.

This phenomenon has also contributed significantly to the current boom in collagen biostimulators, which are increasingly used to improve skin quality, firmness, and tissue support.

Losing weight is important, but it is equally important to know when to stop. Medical supervision, preservation of muscle mass, and a personalized aesthetic strategy should accompany this journey.